


**Pacific Blue™ anti-human CD62L**

<b>Catalog # / Size:</b>	2124125 / 25 µg 2124130 / 100 µg
<b>Clone:</b>	DREG-56
<b>Isotype:</b>	Mouse IgG1, κ
<b>Reactivity:</b>	Human
<b>Preparation:</b>	The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions. The solution is free of unconjugated Pacific Blue™.
<b>Formulation:</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Workshop Number:</b>	V S056
<b>Concentration:</b>	0.5



Human peripheral blood lymphocytes stained with DREG-56 Pacific Blue™

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 microg per 10<sup>6</sup> cells in 100 microL volume or 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

\* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.

**Application Notes:** Additional reported applications (for the relevant formats) include: Western blotting<sup>2,3,9</sup> and *in vitro* blocking of lymphocytes binding to high endothelial venules (HEV)<sup>2</sup>. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 304812).

- Application References:**
- Schlossman S, *et al.* Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  - Kishimoto TK, *et al.* 1990. *Proc. Natl. Acad. Sci. USA* 87:2244. (WB, Block)
  - Jutila M, *et al.* 2002. *J. Immunol.* 169:1768. (WB)
  - Tamassia N, *et al.* 2008. *J. Immunol.* 181:6563. (FC) [PubMed](#)
  - Kmieciak M, *et al.* 2009. *J. Transl. Med.* 7:89. (FC) [PubMed](#)
  - Thakral D, *et al.* 2008. *J. Immunol.* 180:7431. (FC) [PubMed](#)
  - Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
  - Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
  - Koenig JM, *et al.* 1996. *Pediatr. Res.* 39:616. (WB)
  - Shi C, *et al.* 2011. *J. Immunol.* 187:5293. (FC) [PubMed](#)
  - Burges M, *et al.* 2013. *Clin Cancer Res.* 19:5675. [PubMed](#)
  - Cash JL, *et al.* 2013. *EMBO Rep.* 14:999. (FC) [PubMed](#)

**Description:** CD62L is a 74-95 kD single chain type I glycoprotein referred to as L-selectin or LECAM-1. It is expressed on most peripheral blood B cells, subsets of T and NK cells, monocytes, granulocytes, and certain hematopoietic malignant cells. CD62L

binds to carbohydrates present on certain glycoforms of CD34, glycam-1, and MAdCAM-1 and with a low affinity to anionic oligosaccharide sequences related to sialylated Lewis X (sLex, CD15s) through its C-type lectin domain. CD62L is important for the homing of naïve lymphocytes to high endothelial venules in peripheral lymph nodes and Peyer's patches. It also plays a role in leukocyte rolling on activated endothelial cells.

**Antigen**  
**References:**

1. Kishimoto T, *et al.* 1990. *P. Natl. Acad. Sci. USA* 87:2244.
2. Kishimoto T, *et al.* 1991. *Blood* 78:805.